vs

Side-by-side financial comparison of ESCALADE INC (ESCA) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $62.6M, roughly 1.4× ESCALADE INC). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 5.9%, a 16.9% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -2.2%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $13.7M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 4.5%).

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

ESCA vs FDMT — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.4× larger
FDMT
$85.1M
$62.6M
ESCA
Growing faster (revenue YoY)
FDMT
FDMT
+8508902.2% gap
FDMT
8508900.0%
-2.2%
ESCA
Higher net margin
FDMT
FDMT
16.9% more per $
FDMT
22.8%
5.9%
ESCA
More free cash flow
FDMT
FDMT
$14.8M more FCF
FDMT
$28.5M
$13.7M
ESCA
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
4.5%
ESCA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESCA
ESCA
FDMT
FDMT
Revenue
$62.6M
$85.1M
Net Profit
$3.7M
$19.4M
Gross Margin
27.7%
Operating Margin
8.2%
17.3%
Net Margin
5.9%
22.8%
Revenue YoY
-2.2%
8508900.0%
Net Profit YoY
37.1%
139.1%
EPS (diluted)
$0.27
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESCA
ESCA
FDMT
FDMT
Q4 25
$62.6M
$85.1M
Q3 25
$67.8M
$90.0K
Q2 25
$54.3M
$15.0K
Q1 25
$55.5M
$14.0K
Q4 24
$63.9M
$1.0K
Q3 24
$67.7M
$3.0K
Q2 24
$62.5M
$5.0K
Q1 24
$57.3M
$28.0K
Net Profit
ESCA
ESCA
FDMT
FDMT
Q4 25
$3.7M
$19.4M
Q3 25
$5.6M
$-56.9M
Q2 25
$1.8M
$-54.7M
Q1 25
$2.6M
$-48.0M
Q4 24
$2.7M
Q3 24
$5.7M
$-43.8M
Q2 24
$2.8M
$-35.0M
Q1 24
$1.8M
$-32.4M
Gross Margin
ESCA
ESCA
FDMT
FDMT
Q4 25
27.7%
Q3 25
28.1%
Q2 25
24.7%
Q1 25
26.7%
Q4 24
24.9%
Q3 24
24.8%
Q2 24
24.2%
Q1 24
25.0%
Operating Margin
ESCA
ESCA
FDMT
FDMT
Q4 25
8.2%
17.3%
Q3 25
10.8%
-67983.3%
Q2 25
4.8%
-396373.3%
Q1 25
6.6%
-383007.1%
Q4 24
7.1%
Q3 24
11.8%
-1704400.0%
Q2 24
7.1%
-849120.0%
Q1 24
5.3%
-136200.0%
Net Margin
ESCA
ESCA
FDMT
FDMT
Q4 25
5.9%
22.8%
Q3 25
8.2%
-63195.6%
Q2 25
3.4%
-364386.7%
Q1 25
4.7%
-342657.1%
Q4 24
4.2%
Q3 24
8.4%
-1461433.3%
Q2 24
4.5%
-699060.0%
Q1 24
3.1%
-115717.9%
EPS (diluted)
ESCA
ESCA
FDMT
FDMT
Q4 25
$0.27
$0.43
Q3 25
$0.40
$-1.01
Q2 25
$0.13
$-0.98
Q1 25
$0.19
$-0.86
Q4 24
$0.20
Q3 24
$0.40
$-0.79
Q2 24
$0.20
$-0.63
Q1 24
$0.13
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESCA
ESCA
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$402.7M
Total DebtLower is stronger
$18.5M
Stockholders' EquityBook value
$173.2M
$505.7M
Total Assets
$222.1M
$566.7M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESCA
ESCA
FDMT
FDMT
Q4 25
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
Q2 24
$541.9M
Q1 24
$525.9M
Total Debt
ESCA
ESCA
FDMT
FDMT
Q4 25
$18.5M
Q3 25
Q2 25
Q1 25
Q4 24
$25.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESCA
ESCA
FDMT
FDMT
Q4 25
$173.2M
$505.7M
Q3 25
$172.3M
$369.0M
Q2 25
$168.3M
$420.9M
Q1 25
$168.8M
$469.7M
Q4 24
$169.0M
$510.6M
Q3 24
$170.1M
$552.9M
Q2 24
$166.0M
$588.3M
Q1 24
$164.7M
$600.6M
Total Assets
ESCA
ESCA
FDMT
FDMT
Q4 25
$222.1M
$566.7M
Q3 25
$232.5M
$424.0M
Q2 25
$218.3M
$473.6M
Q1 25
$222.1M
$515.7M
Q4 24
$226.3M
$560.4M
Q3 24
$244.9M
$604.0M
Q2 24
$243.1M
$620.1M
Q1 24
$256.3M
$629.9M
Debt / Equity
ESCA
ESCA
FDMT
FDMT
Q4 25
0.11×
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESCA
ESCA
FDMT
FDMT
Operating Cash FlowLast quarter
$14.9M
$28.6M
Free Cash FlowOCF − Capex
$13.7M
$28.5M
FCF MarginFCF / Revenue
21.8%
33.5%
Capex IntensityCapex / Revenue
2.0%
0.1%
Cash ConversionOCF / Net Profit
4.02×
1.47×
TTM Free Cash FlowTrailing 4 quarters
$28.5M
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESCA
ESCA
FDMT
FDMT
Q4 25
$14.9M
$28.6M
Q3 25
$-965.0K
$-46.5M
Q2 25
$13.3M
$-43.4M
Q1 25
$3.8M
$-47.8M
Q4 24
$12.3M
$-134.6M
Q3 24
$10.5M
$-29.4M
Q2 24
$13.3M
$-30.2M
Q1 24
$7.0K
$-29.1M
Free Cash Flow
ESCA
ESCA
FDMT
FDMT
Q4 25
$13.7M
$28.5M
Q3 25
$-1.3M
$-46.6M
Q2 25
$12.9M
$-43.4M
Q1 25
$3.2M
$-48.4M
Q4 24
$11.7M
$-138.4M
Q3 24
$10.2M
$-31.2M
Q2 24
$12.5M
$-30.6M
Q1 24
$-350.0K
$-29.8M
FCF Margin
ESCA
ESCA
FDMT
FDMT
Q4 25
21.8%
33.5%
Q3 25
-1.9%
-51765.6%
Q2 25
23.7%
-289620.0%
Q1 25
5.9%
-345635.7%
Q4 24
18.4%
-13837100.0%
Q3 24
15.0%
-1038966.7%
Q2 24
20.0%
-611840.0%
Q1 24
-0.6%
-106421.4%
Capex Intensity
ESCA
ESCA
FDMT
FDMT
Q4 25
2.0%
0.1%
Q3 25
0.4%
101.1%
Q2 25
0.8%
440.0%
Q1 25
1.0%
4507.1%
Q4 24
0.9%
378600.0%
Q3 24
0.5%
59266.7%
Q2 24
1.3%
6980.0%
Q1 24
0.6%
2535.7%
Cash Conversion
ESCA
ESCA
FDMT
FDMT
Q4 25
4.02×
1.47×
Q3 25
-0.17×
Q2 25
7.28×
Q1 25
1.45×
Q4 24
4.55×
Q3 24
1.85×
Q2 24
4.67×
Q1 24
0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons